Back to results
US 2012/0015899 A1Published application
Modified plant virus particles and uses therefor
AssigneesPlant Bioscience Limited, Aura Biosciences, Inc.
InventorsGeorge Lomonossoff, David Evans, Elisabet de los Pinos, Frank Sainsbury
Life of this patent
Estimating the term…
Abstract
Aspects of the invention provide modified virus-like particles that are designed for therapeutic applications. In particular, aspects of the invention provide CCMV coat proteins that are modified to generate virus-like particles, including mosaic virus-like particles, that can package and/or deliver one or more diagnostic and/or therapeutic agents. The invention also provides methods for treating subjects with one or more modified virus-like particles.
Claims24
1-91. (canceled)
A virus-like particle (VLP) preparation comprising:
- (a) a mosaic VLP of two or more different CCMV coat proteins, wherein at least one of the coat proteins is modified to include a targeting peptide that comprises an integrin-binding motif, and wherein
- (i) at least one of the coat proteins has a N-terminal deletion within the first 26 amino acids and wherein the deletion is of 1 to 26 amino acids in length,
- (ii) at least one of the coat proteins comprises an amino acid sequence of a bacteriophage coat protein or functional portion thereof,
- (iii) at least one of the coat proteins comprises one or more amino acid substitutions within the first 26 N-terminal amino acids and/or the coat protein comprises one or more amino acid substitutions and/or amino acid deletions within amino acids 52-176 of the coat protein,
- (iv) at least one of the coat proteins comprises a moiety selected from the group consisting of polyethylene glycol (PEG), hyaluronic acid, a natural or synthetic polymer, a histidine tag, folic acid, a second targeting peptide not comprising an integrin-binding sequence, an antibody or functional fragment thereof, and a receptor ligand molecule,
- (v) at least one of the coat proteins comprises an amino acid sequence that interacts selectively with a nucleic acid motif that is present on a heterologous RNA molecule;
- (b) a heterologous RNA molecule, wherein the heterologous RNA molecule is a microRNA (miRNA), a short interfering RNA (siRNA), a double-stranded RNA (dsRNA), a short hairpin RNA (shRNA), RNAu, or an antisense RNA molecule;
- and
- (c) a therapeutic molecule, wherein the therapeutic molecule is a therapeutic agent, a diagnostic agent or an imaging agent present in the interior of the assembled mosaic VLP.
6 more elements
A pharmaceutical composition comprising:
- (a) a mosaic VLP of two or more different CCMV coat proteins, wherein at least one of the coat proteins is modified to include a targeting peptide that comprises an integrin-binding motif, and wherein
- (i) at least one of the coat proteins has a N-terminal deletion within the first 26 amino acids and the deletion is of 1 to 26 amino acids in length,
- (ii) at least one of the coat proteins comprises an amino acid sequence of a bacteriophage coat protein or functional portion thereof,
- (iii) at least one of the coat proteins comprises one or more amino acid substitutions within the first 26 N-terminal amino acids and/or the coat protein comprises one or more amino acid substitutions and/or amino acid deletions within amino acids 52-176 of the coat protein,
- (iv) at least one of the coat proteins comprises a moiety selected from the group consisting of polyethylene glycol (PEG), hyaluronic acid, a natural or synthetic polymer, a histidine tag, folic acid, a second targeting peptide not comprising an integrin-binding sequence, an antibody or functional fragment thereof, and a receptor ligand molecule,
- (v) at least one of the coat proteins comprises an amino acid sequence that interacts selectively with a nucleic acid motif that is present on a heterologous RNA molecule;
- (b) a heterologous RNA molecule, wherein the heterologous RNA molecule is a microRNA (miRNA), a short interfering RNA (siRNA), a double-stranded RNA (dsRNA), a short hairpin RNA (shRNA), RNAu, or an antisense RNA molecule;
- and
- (c) a therapeutic molecule, wherein the therapeutic molecule is a therapeutic agent, a diagnostic agent or an imaging agent present in the interior of the assembled mosaic VLP.
6 more elements
Dependencies are inferred from the claim text.